QQQ   312.04 (+0.10%)
AAPL   156.95 (+4.06%)
MSFT   263.18 (-0.54%)
META   193.83 (+2.68%)
GOOGL   107.34 (-0.37%)
AMZN   108.10 (-4.26%)
TSLA   197.74 (+5.03%)
NVDA   216.18 (-0.42%)
NIO   11.74 (-1.84%)
BABA   107.08 (-2.42%)
AMD   87.86 (-0.51%)
T   19.88 (-1.97%)
F   13.49 (-5.80%)
MU   63.56 (+0.62%)
CGC   3.06 (-2.55%)
GE   82.94 (-1.19%)
DIS   112.50 (-0.63%)
AMC   6.68 (+9.87%)
PFE   44.19 (-0.34%)
PYPL   87.71 (+0.86%)
NFLX   377.39 (+2.86%)
QQQ   312.04 (+0.10%)
AAPL   156.95 (+4.06%)
MSFT   263.18 (-0.54%)
META   193.83 (+2.68%)
GOOGL   107.34 (-0.37%)
AMZN   108.10 (-4.26%)
TSLA   197.74 (+5.03%)
NVDA   216.18 (-0.42%)
NIO   11.74 (-1.84%)
BABA   107.08 (-2.42%)
AMD   87.86 (-0.51%)
T   19.88 (-1.97%)
F   13.49 (-5.80%)
MU   63.56 (+0.62%)
CGC   3.06 (-2.55%)
GE   82.94 (-1.19%)
DIS   112.50 (-0.63%)
AMC   6.68 (+9.87%)
PFE   44.19 (-0.34%)
PYPL   87.71 (+0.86%)
NFLX   377.39 (+2.86%)
QQQ   312.04 (+0.10%)
AAPL   156.95 (+4.06%)
MSFT   263.18 (-0.54%)
META   193.83 (+2.68%)
GOOGL   107.34 (-0.37%)
AMZN   108.10 (-4.26%)
TSLA   197.74 (+5.03%)
NVDA   216.18 (-0.42%)
NIO   11.74 (-1.84%)
BABA   107.08 (-2.42%)
AMD   87.86 (-0.51%)
T   19.88 (-1.97%)
F   13.49 (-5.80%)
MU   63.56 (+0.62%)
CGC   3.06 (-2.55%)
GE   82.94 (-1.19%)
DIS   112.50 (-0.63%)
AMC   6.68 (+9.87%)
PFE   44.19 (-0.34%)
PYPL   87.71 (+0.86%)
NFLX   377.39 (+2.86%)
QQQ   312.04 (+0.10%)
AAPL   156.95 (+4.06%)
MSFT   263.18 (-0.54%)
META   193.83 (+2.68%)
GOOGL   107.34 (-0.37%)
AMZN   108.10 (-4.26%)
TSLA   197.74 (+5.03%)
NVDA   216.18 (-0.42%)
NIO   11.74 (-1.84%)
BABA   107.08 (-2.42%)
AMD   87.86 (-0.51%)
T   19.88 (-1.97%)
F   13.49 (-5.80%)
MU   63.56 (+0.62%)
CGC   3.06 (-2.55%)
GE   82.94 (-1.19%)
DIS   112.50 (-0.63%)
AMC   6.68 (+9.87%)
PFE   44.19 (-0.34%)
PYPL   87.71 (+0.86%)
NFLX   377.39 (+2.86%)
NASDAQ:DVAX

Dynavax Technologies - DVAX Stock Forecast, Price & News

$11.85
-0.03 (-0.25%)
(As of 02/3/2023 11:47 AM ET)
Add
Compare
Today's Range
$11.64
$11.92
50-Day Range
$10.27
$12.72
52-Week Range
$7.26
$17.48
Volume
248,183 shs
Average Volume
1.32 million shs
Market Capitalization
$1.51 billion
P/E Ratio
5.72
Dividend Yield
N/A
Price Target
$21.50

Dynavax Technologies MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
83.8% Upside
$21.50 Price Target
Short Interest
Bearish
10.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.59
Upright™ Environmental Score
News Sentiment
1.18mentions of Dynavax Technologies in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$18.05 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From $1.95 to ($0.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

127th out of 1,029 stocks

Pharmaceutical Preparations Industry

52nd out of 501 stocks

DVAX stock logo

About Dynavax Technologies (NASDAQ:DVAX) Stock

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Receive DVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter.

DVAX Stock News Headlines

Dynavax Technologies (NASDAQ:DVAX) Sees Strong Trading Volume
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
DVAX.OQ - | Stock Price & Latest News | Reuters
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Dynavax Stock Gaps Down On Today's Open (DVAX)
I'm Going to Give This Biotech Another Shot
Dynavax to Present at Two Upcoming Investor Conferences
DVAX Dynavax Technologies Corporation
See More Headlines
Receive DVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter.

DVAX Company Calendar

Last Earnings
11/04/2021
Today
2/03/2023
Next Earnings (Estimated)
2/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:DVAX
CUSIP
26815810
Employees
311
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$21.50
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+81.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$76.71 million
Pretax Margin
44.58%

Debt

Sales & Book Value

Annual Sales
$439.44 million
Cash Flow
$1.04 per share
Book Value
$1.85 per share

Miscellaneous

Free Float
115,707,000
Market Cap
$1.51 billion
Optionable
Optionable
Beta
1.42

Social Links


Key Executives

  • Ryan SpencerRyan Spencer
    Chief Executive Officer & Director
  • David F. NovackDavid F. Novack
    President & Chief Operating Officer
  • Kelly MacDonaldKelly MacDonald
    Chief Financial Officer & Senior Vice President
  • Robert JanssenRobert Janssen
    Chief Medical Officer & SVP-Clinical Development
  • Todd Lopeman
    Vice President-Technical Operations













DVAX Stock - Frequently Asked Questions

Should I buy or sell Dynavax Technologies stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DVAX shares.
View DVAX analyst ratings
or view top-rated stocks.

What is Dynavax Technologies' stock price forecast for 2023?

2 Wall Street analysts have issued 1 year target prices for Dynavax Technologies' stock. Their DVAX share price forecasts range from $21.00 to $22.00. On average, they anticipate the company's share price to reach $21.50 in the next twelve months. This suggests a possible upside of 81.0% from the stock's current price.
View analysts price targets for DVAX
or view top-rated stocks among Wall Street analysts.

How have DVAX shares performed in 2023?

Dynavax Technologies' stock was trading at $10.64 at the beginning of 2023. Since then, DVAX stock has increased by 11.7% and is now trading at $11.88.
View the best growth stocks for 2023 here
.

When is Dynavax Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our DVAX earnings forecast
.

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) issued its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $0.05 by $0.29. The biopharmaceutical company earned $108.27 million during the quarter, compared to analysts' expectations of $77.30 million. Dynavax Technologies had a trailing twelve-month return on equity of 90.54% and a net margin of 44.35%. During the same period last year, the company posted ($0.15) earnings per share.

What is Eddie Gray's approval rating as Dynavax Technologies' CEO?

13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend.

What other stocks do shareholders of Dynavax Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA).

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Who are Dynavax Technologies' major shareholders?

Dynavax Technologies' stock is owned by a variety of institutional and retail investors. Top institutional investors include Chicago Capital LLC (4.59%), Nisa Investment Advisors LLC (0.28%), Congress Asset Management Co. MA (0.16%), New York State Teachers Retirement System (0.11%), New York State Common Retirement Fund (0.11%) and Monarch Partners Asset Management LLC (0.10%). Insiders that own company stock include Andrew A F Hack, David F Novack, David F Novack, Francis Cano, Justin Burgess, Robert Janssen and Ryan Spencer.
View institutional ownership trends
.

How do I buy shares of Dynavax Technologies?

Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dynavax Technologies' stock price today?

One share of DVAX stock can currently be purchased for approximately $11.88.

How much money does Dynavax Technologies make?

Dynavax Technologies (NASDAQ:DVAX) has a market capitalization of $1.52 billion and generates $439.44 million in revenue each year. The biopharmaceutical company earns $76.71 million in net income (profit) each year or $2.07 on an earnings per share basis.

How many employees does Dynavax Technologies have?

The company employs 311 workers across the globe.

How can I contact Dynavax Technologies?

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The official website for the company is www.dynavax.com. The biopharmaceutical company can be reached via phone at (510) 848-5100, via email at ir@dynavax.com, or via fax at 510-848-1327.

This page (NASDAQ:DVAX) was last updated on 2/3/2023 by MarketBeat.com Staff